Healthleap Secures $38M to Expand AI-Driven Hospital Risk Identification Across 40+ Conditions

Healthleap, a South Africa-founded startup building an AI platform that parses patient records to flag potential undiagnosed illnesses, has closed $38 million in seed and Series A funding, TechCrunch has learned exclusively. The round comprises an $8 million seed led by Sequoia Capital and First Round Capital, and a $30 million Series A led by Hummingbird Ventures. The group did not disclose Healthleap’s valuation. Founded in 2022 by siblings Jemima and Josiah Meyer, Healthleap began with a clinical nutrition tool designed for dietitians before pivoting to a broader platform.

The current aim is to identify hospitalized patients who might be suffering from conditions that often go missed—such as malnutrition or delirium—and to bring these concerns to clinicians’ attention earlier in a patient’s stay, according to co-founder and CEO Josiah Meyer. The platform works by connecting to a hospital’s electronic health record (EHR) system and pulling data from both structured fields (labs, vital signs, weights) and unstructured clinician notes. It then uses language models to extract affirmative or negated mentions of relevant clinical concepts (for example, recent weight loss or swallowing difficulties). This information is combined with traditional data such as lab results and vitals to generate a risk score for each inpatient. The software does not diagnose conditions; instead it surfaces items for further review and integrates into the care team’s existing workflow via a dashboard that surfaces patient trends each morning. Healthleap currently operates in more than 50 hospitals, screening for conditions like malnutrition and delirium, and it has developed programs to detect aspiration pneumonia, pressure ulcers, and risks of readmission for congestive heart failure—areas that are undergoing additional clinical validation.

The company notes its platform is designed to be easily extensible to support more conditions. Malnutrition, in particular, has been a focal point for Healthleap because it frequently remains undiagnosed and can hinder recovery. Studies have reported that a sizable share of hospital inpatients are malnourished, with links to longer stays, slower wound healing, higher infection rates, and increased morbidity and mortality. Josiah said Healthleap’s growth over the last year has included an expansion from three hospital partners to more than 50, with customers including Penn Medicine, Cedars-Sinai, Intermountain, Houston Methodist, and Emory Healthcare. While he declined to share exact revenue figures, he noted revenue has risen more than tenfold during the period. Pricing for Healthleap’s platform is three-year contracts based on a hospital’s licensed bed count, plus an outcome-based component.

The company emphasizes a strong, measurable ROI: every customer to date has achieved at least a 5x hard ROI, with some reporting more than 20x total ROI when considering financial and operational benefits. An example of the platform’s impact is its engagement at the Hospital of the University of Pennsylvania, where Healthleap’s malnutrition program contributed an estimated $23.8 million in annualized financial impact, including $6.3 million in additional reimbursements and $17.5 million from shorter lengths of stay.

Healthleap plans to invest the fresh capital in engineering, product development, sales, and customer success as it broadens coverage to more conditions. The company’s longer-term ambition is to monitor and assist with more than 40 major health conditions and to extend its reach into outpatient and home-care settings. Healthleap’s approach represents a broader shift toward AI-assisted clinical review, aiming to supplement clinicians’ assessments rather than replace human judgment. As hospitals seek to improve outcomes and control costs, the startup’s model highlights the potential for AI to surface clinically relevant signals embedded in narrative notes alongside traditional data streams.